The Pharmacokinetic Characteristics and Safety Between HIP2001 and HGP2001 in Healthy Volunteers
Primary Purpose
Atrial Fibrillation
Status
Completed
Phase
Phase 1
Locations
Korea, Republic of
Study Type
Interventional
Intervention
HIP2001
HGP2001
Sponsored by
About this trial
This is an interventional treatment trial for Atrial Fibrillation
Eligibility Criteria
Inclusion Criteria:
- 19 kg/m^2 ≤ BMI < 28 kg/m^2, weight >60kg
- 90 mmHg ≤ SBP <140 mmHg, 50 mmHg ≤ DBP <900 mmHg
- agrees that the person, spouse, or partner uses appropriate medically recognized contraception and does not provide sperm or eggs from the date of administration of the first investigational drug to 7 days after the administration of the last investigational drug.
Exclusion Criteria:
- A history of hypersensitivity reactions or clinically significant hypersensitivity reactions
- A history of gastrointestinal diseases or surgery that may affect the absorption of clinical trial drugs
- A history of substance abuse or who test positive for drugs of concern for abuse in the urine drug screening test
- Positive results of serological tests
- Have taken other investigational drugs or bioequivalence drugs within 6 months before the first administration of the investigational drug
- Donated whole blood within 60 days prior to the screening date or donated components within 30 days or received a blood transfusion within 30 days
- Have drank more than 210 g/week of alcohol within 30 days before the screening date
- Have smoked more than 10 bills/day within 30 days before the screening date
- AST, ALT value is more than 2 times the UNL or bilirubin level is more than 1.5 times the UNL, eGFR < 50 mL/min/1.73m2, Prothrombin (INR) > 1.31 INR or aPTT > 39.7 sec
- 12-ECG QTc >450 ms
Sites / Locations
- Jeonbuk University Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Other
Other
Arm Label
Sequence 1
Sequence 2
Arm Description
Period 1: HGP2001, Period 2: HIP2001
Period 1: HIP2001, Period 2: HGP2001
Outcomes
Primary Outcome Measures
AUCt
Pharmacokinetic evaluation
Cmax
Pharmacokinetic evaluation
Secondary Outcome Measures
AUCinf
Pharmacokinetic evaluation
Tmax
Pharmacokinetic evaluation
t1/2
Pharmacokinetic evaluation
CL/F
Pharmacokinetic evaluation
Vd/F
Pharmacokinetic evaluation
Full Information
NCT ID
NCT04764201
First Posted
February 15, 2021
Last Updated
March 30, 2021
Sponsor
Hanmi Pharmaceutical Company Limited
1. Study Identification
Unique Protocol Identification Number
NCT04764201
Brief Title
The Pharmacokinetic Characteristics and Safety Between HIP2001 and HGP2001 in Healthy Volunteers
Official Title
A Randomized, Open Label, Single Dose, 2-way Crossover Clinical Trial to Evaluate the Pharmacokinetic Characteristics and Safety Between HIP2001 and HGP2001 in Healthy Volunteers
Study Type
Interventional
2. Study Status
Record Verification Date
March 2021
Overall Recruitment Status
Completed
Study Start Date
January 16, 2021 (Actual)
Primary Completion Date
February 26, 2021 (Actual)
Study Completion Date
March 8, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hanmi Pharmaceutical Company Limited
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
The purpose of this study is to evaluate the pharmacokinetic characteristics and safety between HIP2001 and HGP2001 in healthy volunteers.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atrial Fibrillation
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
50 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Sequence 1
Arm Type
Other
Arm Description
Period 1: HGP2001, Period 2: HIP2001
Arm Title
Sequence 2
Arm Type
Other
Arm Description
Period 1: HIP2001, Period 2: HGP2001
Intervention Type
Drug
Intervention Name(s)
HIP2001
Intervention Description
Test drug
Intervention Type
Drug
Intervention Name(s)
HGP2001
Intervention Description
Reference drug
Primary Outcome Measure Information:
Title
AUCt
Description
Pharmacokinetic evaluation
Time Frame
0~48 hours
Title
Cmax
Description
Pharmacokinetic evaluation
Time Frame
0~48 hours
Secondary Outcome Measure Information:
Title
AUCinf
Description
Pharmacokinetic evaluation
Time Frame
0~48 hours
Title
Tmax
Description
Pharmacokinetic evaluation
Time Frame
0~48 hours
Title
t1/2
Description
Pharmacokinetic evaluation
Time Frame
0~48 hours
Title
CL/F
Description
Pharmacokinetic evaluation
Time Frame
0~48 hours
Title
Vd/F
Description
Pharmacokinetic evaluation
Time Frame
0~48 hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
19 kg/m^2 ≤ BMI < 28 kg/m^2, weight >60kg
90 mmHg ≤ SBP <140 mmHg, 50 mmHg ≤ DBP <900 mmHg
agrees that the person, spouse, or partner uses appropriate medically recognized contraception and does not provide sperm or eggs from the date of administration of the first investigational drug to 7 days after the administration of the last investigational drug.
Exclusion Criteria:
A history of hypersensitivity reactions or clinically significant hypersensitivity reactions
A history of gastrointestinal diseases or surgery that may affect the absorption of clinical trial drugs
A history of substance abuse or who test positive for drugs of concern for abuse in the urine drug screening test
Positive results of serological tests
Have taken other investigational drugs or bioequivalence drugs within 6 months before the first administration of the investigational drug
Donated whole blood within 60 days prior to the screening date or donated components within 30 days or received a blood transfusion within 30 days
Have drank more than 210 g/week of alcohol within 30 days before the screening date
Have smoked more than 10 bills/day within 30 days before the screening date
AST, ALT value is more than 2 times the UNL or bilirubin level is more than 1.5 times the UNL, eGFR < 50 mL/min/1.73m2, Prothrombin (INR) > 1.31 INR or aPTT > 39.7 sec
12-ECG QTc >450 ms
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mingeul Kim
Organizational Affiliation
Jeonbuk University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Jeonbuk University Hospital
City
Jeonju
Country
Korea, Republic of
12. IPD Sharing Statement
Learn more about this trial
The Pharmacokinetic Characteristics and Safety Between HIP2001 and HGP2001 in Healthy Volunteers
We'll reach out to this number within 24 hrs